Synfini

United States
New Lisbon, Wisconsin, United States

Company profile

Synfini company profile

Synfini provides an AI-powered drug discovery platform that supports the full chemistry workflow—from molecular design through synthesis, testing, analysis, and data management. Its suite includes SynPlan for project planning and tracking, SynDesign for generating optimized molecules with minimal data, SynRoute for AI-assisted synthesis pathway planning, SynBuild for automated compound production, and SynDB as a centralized reaction and molecular data repository. The platform enables scientists to collaborate seamlessly, customize workflows, and accelerate hit-to-lead and lead optimization stages with efficiency and precision. Synfini also engages in partnerships with biotech firms like Multispan and O₂nix Bio to apply its integrated design-make-test-analyze system to challenging targets such as GPCRs and cancer‑related enzymes.

Business identity

Contact email
[email protected]
Phone number
650-283-5939
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2023-01-01, Year

Headquarters

Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding rounds
3
Total equity funding
$8.9M
Last funding
Series Unknown / $8.9M / 2025-07-07
Last equity funding
Series Unknown / $8.9M
Investors
9
Lead investors
1
Founders
3
Articles
28

Founders and investors

Founders

Doug DonzelliNathan CollinsPeter Madrid

Lead investors

JSL Health Capital

Investors

Ferocity CapitalFoothill VenturesGaingelsMana VenturesTrust Ventures